The Prognostic Impact of Minimally Invasive Esophagectomy on Survival after Esophagectomy following a Delayed Interval after Chemoradiotherapy; A Secondary Analysis of the DICE Study.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
21 Jun 2024
Historique:
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 21 6 2024
Statut: aheadofprint

Résumé

To evaluate prognostic differences between minimally invasive esophagectomy (MIE) and open esophagectomy (OE) in patients with surgery after a prolonged interval (>12 wk) following chemoradiotherapy (CRT). Previously, we established that a prolonged interval after CRT prior to esophagectomy was associated with poorer long-term survival. This was an international multi-center cohort study involving seventeen tertiary centers, including patients who received CRT followed by surgery between 2010-2020. Patients undergoing MIE were defined as thoracoscopic and laparoscopic approach. 428 patients (145 MIE and 283 OE) had surgery between 12 weeks and two years after CRT. Significant differences were observed in ASA grade, radiation dose, clinical T stage, and histological subtype. There were no significant differences between the groups in age, sex, BMI, pathological T or N stage, resection margin status, tumor location, surgical technique, or 90-day mortality. Survival analysis showed MIE was associated with improved survival in univariate (P=0.014), multivariate analysis after adjustment for smoking, T and N stage, and histology (HR=1.69; 95% CI 1.14 to 2.5) and propensity matched analysis (P=0.02). Further subgroup analyses by radiation dose and interval after CRT showed survival advantage for MIE, in 40-50Gy dose groups (HR=1.9; 95% CI 1.2 to 3.0), and in patients having surgery within six months of CRT (HR=1.6; 95% CI 1.1 to 2.2). MIE was associated with an improved overall survival compared to OE in patients with a prolonged interval from CRT to surgery. The mechanism for this observed improvement in survival remains unknown, with potential hypotheses including a reduction in complications and improved functional recovery after MIE.

Sections du résumé

OBJECTIVE OBJECTIVE
To evaluate prognostic differences between minimally invasive esophagectomy (MIE) and open esophagectomy (OE) in patients with surgery after a prolonged interval (>12 wk) following chemoradiotherapy (CRT).
BACKGROUND BACKGROUND
Previously, we established that a prolonged interval after CRT prior to esophagectomy was associated with poorer long-term survival.
METHODS METHODS
This was an international multi-center cohort study involving seventeen tertiary centers, including patients who received CRT followed by surgery between 2010-2020. Patients undergoing MIE were defined as thoracoscopic and laparoscopic approach.
RESULTS RESULTS
428 patients (145 MIE and 283 OE) had surgery between 12 weeks and two years after CRT. Significant differences were observed in ASA grade, radiation dose, clinical T stage, and histological subtype. There were no significant differences between the groups in age, sex, BMI, pathological T or N stage, resection margin status, tumor location, surgical technique, or 90-day mortality. Survival analysis showed MIE was associated with improved survival in univariate (P=0.014), multivariate analysis after adjustment for smoking, T and N stage, and histology (HR=1.69; 95% CI 1.14 to 2.5) and propensity matched analysis (P=0.02). Further subgroup analyses by radiation dose and interval after CRT showed survival advantage for MIE, in 40-50Gy dose groups (HR=1.9; 95% CI 1.2 to 3.0), and in patients having surgery within six months of CRT (HR=1.6; 95% CI 1.1 to 2.2).
CONCLUSION CONCLUSIONS
MIE was associated with an improved overall survival compared to OE in patients with a prolonged interval from CRT to surgery. The mechanism for this observed improvement in survival remains unknown, with potential hypotheses including a reduction in complications and improved functional recovery after MIE.

Identifiants

pubmed: 38904105
doi: 10.1097/SLA.0000000000006411
pii: 00000658-990000000-00949
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Auteurs

Sheraz R Markar (SR)

Department of Surgery, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE, UK.
Nuffield Department of Surgery, University of Oxford, UK.

Bruno Sgromo (B)

Department of Surgery, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE, UK.

Richard Evans (R)

Department of Surgery, Birmingham University Hospitals NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW, UK.

Ewen A Griffiths (EA)

Department of Surgery, Birmingham University Hospitals NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW, UK.

Rita Alfieri (R)

General Gastric and Esophagus Surgery Unit, Humanitas Research Hospital, Italy.
Oncological Surgery Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.

Carlo Castoro (C)

General Gastric and Esophagus Surgery Unit, Humanitas Research Hospital, Italy.

Caroline Gronnier (C)

Esophageal and endocrine surgery unit, digestive surgery department, centre Magellan, CHU de Bordeaux, France.

Christian A Gutschow (CA)

Department of Visceral Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Guillaume Piessen (G)

Department of Digestive and General Surgery, University Hospital Claude Huriez, Lille, Cedex, France.

Giovanni Capovilla (G)

Department of Surgery, University Medical Centre, Johannes Gutenberg University Mainz. Mainz, Germany.

Peter P Grimminger (PP)

Department of Surgery, University Medical Centre, Johannes Gutenberg University Mainz. Mainz, Germany.

Donald E Low (DE)

Department of Thoracic Surgery and Thoracic Oncology, Virginia Mason Hospital & Seattle Medical Center, 1100 Ninth Avenue, Seattle, WA 98101.

James Gossage (J)

Department of Surgery, Guy's and St Thomas' Hospitals NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.

Suzanne S Gisbertz (SS)

Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.

Jelle Ruurda (J)

Department of Upper Gastrointestinal Surgery, University Medical Center Utrecht, Netherlands.

Richard van Hillegersberg (R)

Department of Upper Gastrointestinal Surgery, University Medical Center Utrecht, Netherlands.

Xavier Benoit D'journo (XB)

Department of Thoracic Surgery, Diseases of the Esophagus & Lung Transplantations. Chemin des Bourrely, North Hospital, Marseille, France.

Alexander W Phillips (AW)

Northern Esophago-Gastric Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, Newcastle upon Tyne, NE7 7DN, UK.

Ricardo Rosati (R)

Department of GI Surgery, San Raffaele Hospital, Milan, Italy.

George B Hanna (GB)

Academic Surgical Unit, Department of Surgery and Cancer, Imperial College London, St Mary's Hospital, London, UK.

Nick Maynard (N)

Department of Surgery, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE, UK.

Wayne Hofstetter (W)

University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 445, Houston, TX, United States.

Lorenzo Ferri (L)

Departments of Surgery and Oncology, McGill University, Montreal General Hospital, Cedar Avenue, Montreal, Canada.

Mark I Berge Henegouwen (MI)

Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.

Richard Owen (R)

Department of Surgery, Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road, Oxford, OX3 7LE, UK.
The Ludwig Institute for Cancer Research, University of Oxford, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ, UK.

Classifications MeSH